Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Pitt Retiree Study: A Diabetes Prevention Program for Medicare Eligible Older Adults (PRS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03192475
Recruitment Status : Completed
First Posted : June 20, 2017
Last Update Posted : June 20, 2017
Sponsor:
Information provided by (Responsible Party):
Elizabeth Venditti, University of Pittsburgh

Brief Summary:
The Pitt Retiree Study (PRS) disseminates a novel, yet practical, diabetes prevention program among Medicare eligible adults in Western Pennsylvania. This study will provide 4, and 12 month outcome data (with a no treatment follow-up assessment at 24 months) to help determine whether a continued contact group telephone intervention is feasible and effective in enhancing health outcomes and physical functional ability in high risk adults (aged 65-80) with obesity and cardiometabolic risk factors .

Condition or disease Intervention/treatment Phase
Obesity Cardiovascular Risk Factor Eating Behavior Diet Modification Physical Activity Quality of Life Mobility Limitation Behavioral: GLB plus phone contacts Behavioral: GLB plus newsletter contacts Not Applicable

Detailed Description:
There is substantial evidence that overweight and obesity during late life (≥ 65 years of age) confers significant risk for type 2 diabetes and co-morbid conditions. Thus, there is growing concern about the public health consequences of increased incidence of type 2 diabetes in an aging United States population. Studies with high risk samples have shown that lifestyle interventions significantly reduce diabetes risk and that elders are particularly responsive, showing better weight loss and lower rates of diabetes development in comparison to younger individuals. However, although there have been program dissemination studies with mixed-age adult cohorts, few studies have focused specifically on persons ≥ 65 years of age or addressed the challenges of identifying workable platforms for delivering prevention programs to older adults. This application is based on the premise that offering an evidence-based lifestyle intervention to reduce risk for type 2 diabetes to retirees during the annual Medicare enrollment process presents an innovative, practical opportunity to reach eligible, high-risk adults. If shown to be feasible and effective, this program has strong potential for public health impact and medical cost-containment. Further, although clinical studies have emphasized the importance of continued contact over time in helping individuals extend the benefits of lifestyle interventions, there are no dissemination studies of which we are aware that have systematically documented the impact of continued monthly contacts after the initial intervention period. Thus, the overall aims of this application are to: 1. examine the feasibility and effectiveness of implementing the Group Lifestyle Balance 12-session program (GLB-12), an evidence-supported prevention program to mitigate diabetes risk, as part of the Medicare benefit offered to high risk retirees at a large public university, and; 2. evaluate the utility of continued telephone contact in enhancing treatment outcome at 12-months from baseline. Eligible participants will be 320 adults without diabetes, aged 65-80, with a BMI ≥ 27 and at least one additional cardiometabolic risk factor. All participants will receive the GLB-12 and then will be randomized to one of two continued contact protocols for the remaining one year of intervention, 8-sessions of continued small group contact by telephone (GLB-12 plus 8TC) or a newsletter control condition (GLB-12 plus NC). Program feasibility will be assessed by reporting enrollment, adherence and session completion rates, and satisfaction ratings in this delivery context. Effectiveness of the GLB-12 will be documented by reporting mean percent weight loss and the proportion of participants meeting ≥ 5% weight loss, a commonly accepted benchmark in translation studies known to be associated with favorable cardiometabolic outcomes at month 4. It also is hypothesized that GLB-12 plus 8TC, when compared to GLB-12 plus NC will be associated with more favorable anthropometric (weight, waist), cardiometabolic (glucose, blood pressure, lipid), physical function (chair stand, balance, gait speed) and health related quality of life outcomes at months 12 and 24. Finally, exploratory analyses will document program costs and program impact on medical utilization.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 322 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: An initial translational Group Lifestyle Balance (GLB) in person, lifestyle intervention designed to mitigate cardiometabolic risk in older adults is delivered to all participants between 0 and 4-months. Subsequently, one-half of the enrolled sample is randomized to either (1) 8-group telephone contacts (8-TC) for the remainder of 12-months; the other one-half is randomized to a newsletter control condition (NC) during this time period.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Dissemination of a Diabetes Prevention Program Among Medicare Eligible Older Adults
Actual Study Start Date : January 28, 2013
Actual Primary Completion Date : May 26, 2017
Actual Study Completion Date : May 26, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Medicare

Arm Intervention/treatment
Active Comparator: GLB plus phone contacts
GLB is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
Behavioral: GLB plus phone contacts
GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.

Placebo Comparator: GLB plus newsletter contacts
GLB is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
Behavioral: GLB plus newsletter contacts
GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.




Primary Outcome Measures :
  1. Change in bodyweight [ Time Frame: change from baseline bodyweight at 12-months ]
    percent weight loss


Secondary Outcome Measures :
  1. Change in waist circumference [ Time Frame: change from baseline circumference at 12-months ]
    waist measure (cm)

  2. Change in blood pressure [ Time Frame: change from baseline level at 12-months ]
    systolic, diastolic blood pressure (mmHg)

  3. Change in fasting glucose [ Time Frame: change from baseline level at 12-months ]
    fasting glucose (mg/dl)

  4. Change in fasting total cholesterol [ Time Frame: change from baseline score at 12-months ]
    total cholesterol (mg/dl) measured by finger-stick blood sample

  5. Change in fasting HDL (high-density lipoprotein) cholesterol [ Time Frame: change from baseline level at 12-months ]
    HDL-c (mg/dl) measured by finger-stick blood sample

  6. Change in fasting LDL (low-density lipoprotein) cholesterol [ Time Frame: change from baseline level at 12-months ]
    LDL-c (mg/dl) measured by finger-stick blood sample

  7. Change in fasting triglycerides [ Time Frame: change from baseline level at 12-months ]
    Triglycerides (mg/dl)

  8. Change in nutrition [ Time Frame: change from baseline score at 12-months ]
    Mediterranean Diet History Questionnaire

  9. Change in physical function [ Time Frame: change from baseline score at 12-months ]
    Short Physical Performance Battery (Gait Speed, Chair Stand, Balance)

  10. Change in physical activity minutes/per week [ Time Frame: change from baseline activity level at 12-months ]
    CHAMPS questionnaire for older adults

  11. Change in health related quality of life [ Time Frame: change from baseline score at 12-months ]
    Medical Outcomes Study Short-Form (SF-12)

  12. Change in mood [ Time Frame: change from baseline score at 12-months ]
    Center for Epidemiological Studies Depression Scale (CES-D)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 80 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Men and women, ages 65-80, with a BMI ≥ 27 and at least one of the following additional risk factors will be included: 1) Large waist circumference (> 40 inches men, >35 inches women) 2) hypertension or taking hypertension medication; 3) elevated lipids or taking medication for lipids or triglycerides 4) pre-diabetes (fasting glucose ≥ 100 mg/dL and < 126 mg/DL OR 5) or a score of 15 on the American Diabetes Association (ADA) risk test.

All study participants must have access to a telephone (including appropriate assistive devices if there are hearing impairments) and be able to read at the 6th grade level.

Exclusion Criteria:

  • Individuals who report that they have been diagnosed by their doctor with diabetes or that they are taking any medicines used to treat diabetes
  • lack of physician clearance for exercise participation before the 4th session
  • a weight loss of 4.5 kgs or more in the past six months (to rule out unintentional weight loss that may be an indicator of current or incipient physical illness)
  • current use of weight loss medications
  • unable to attend at least 75% of the GLB 12-session program or are unwilling to self-monitor food, activity and weight as prescribed will be excluded and encouraged to consider joining in subsequent years.

Excluded individuals are referred to other clinical resources as appropriate.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03192475


Sponsors and Collaborators
University of Pittsburgh
Investigators
Layout table for investigator information
Principal Investigator: Elizabeth M Venditti, PhD University of Pittsburgh

Layout table for additonal information
Responsible Party: Elizabeth Venditti, Assistant Professor of Psychiatry and Epidemiology, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT03192475     History of Changes
Other Study ID Numbers: PRO12050022
First Posted: June 20, 2017    Key Record Dates
Last Update Posted: June 20, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: At the time of application in 2011 no formal data sharing plan was proposed, no designated funds were requested for archiving with a repository, and the R18 application was less than the $500,000 per year threshold set for data sharing. However, under my own auspices (as PI) I do plan to share the final research data with colleagues (post-doctoral students and junior faculty, co-investigators at my institution across several departments including Medicine, Psychiatry, Epidemiology/Public Health). All data is de-identified per the original Data Safety and Monitoring Plan. All safeguards will be taken to ensure confidentiality and privacy of participants. I will not place limits on questions or methods of those sharing data files and only require that the Pitt Retiree Study participants be acknowledged on all abstracts and manuscript publications resulting from the final data set.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Mobility Limitation
Signs and Symptoms